Enzyme replacement therapy in Japanese Fabry disease patients: The results of a phase 2 bridging study

Journal of Inherited Metabolic Disease

Volumn 28, Issue 4, 2005, Pages 575-583

  Eto, Yosh ^a,h   Ohashi, T ^a   Utsunomiya, Y ^a   Fujiwara, M ^a   Mizuno, A ^b   Inui, K ^c   Sakai, N ^c   Kitagawa, T ^d   Suzuki, Y ^e   Mochizuki, S ^a   Kawakami, M ^a   Hosoya, T ^a   Owada, M ^d   Sakuraba, H ^f   Saito, H ^g  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CHUBU NATIONAL HOSPITAL   (Japan)

^c OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^d NIHON UNIVERSITY   (Japan)

^e INTERNATIONAL UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^f TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^g NATIONAL CHILDREN S HOSPITAL   (Japan)

^h NONE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE BETA; GLOBOTRIAOSYLCERAMIDE; HYDROXYZINE; IBUPROFEN; IMMUNOGLOBULIN G ANTIBODY; PARACETAMOL;

ADOLESCENT; ADULT; ANTIGEN DETECTION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG FEVER; DRUG INFUSION; DRUG SAFETY; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REPLACEMENT; ETHNIC DIFFERENCE; FABRY DISEASE; HISTOLOGY; HUMAN; HYPERTENSION; JAPAN; KIDNEY FUNCTION; LIMB PAIN; LIPID STORAGE; MALAISE; MALE; MULTICENTER STUDY; OPEN STUDY; PHASE 2 CLINICAL TRIAL; QUALITY OF LIFE; RHINITIS; RIGOR; SEROCONVERSION; X CHROMOSOME LINKED DISORDER;

ADULT; ALPHA-GALACTOSIDASE; CREATININE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FABRY DISEASE; HUMANS; IMMUNOGLOBULIN G; ISOENZYMES; JAPAN; KIDNEY; MALE; METABOLIC CLEARANCE RATE; MYOCARDIUM; SAFETY; SKIN; TREATMENT OUTCOME; TRIHEXOSYLCERAMIDES;

EID: 19944375153     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-005-0575-y     Document Type: Article

References (13)

1. Desnick RJ, Wasserstein MP (2001) Fabry disease: Clinical features and recent advances in enzyme replacement therapy. Adv Nephrol Necker Hosp 31: 317-339.
2. Desnick RJ, Ioannou YA, Eng CM (2001) α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc. eds. The Metabolic and Molecular Bases of Inherited Disease, 8th edn. New York: McGraw-Hill, 3733-3774.
3. Elleder M, Bradova V, Smid F, et al (1990) Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 417(5): 449-455.
4. Eng CM, Banikazemi M, Gordon RE, et al (2001a) A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68(3): 711-722.
5. Eng CM, Guffon N, Wilcox WR, et al (2001b) Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345(1): 9-16.
6. Kolodny EH, Pastores GM (2002) Anderson-Fabry disease: Extrarenal, neurologic manifestations. J Am Soc Nephrol 13(supplement 2): S150-153.
7. Linhart A, Magage S, Palecek T, et al (2002) Cardiac involvement in Fabry disease. Acta Paediatr Suppl 91(439): 15-20.
8. Lyon MF (2002) X-chromosome inactivation and human genetic disease. Acta Paediatr Suppl 91(439): 107-112.
9. Meikle PJ, Hopwood JJ, Clague AE, et al (1999) Prevalence of lysosomal storage disorders. JAMA 281(3): 249-254.
10. Nakao S, Kodama C, Takenaka T, et al (2003) Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a 'renal variant' phenotype. Kidney Int 64(3): 801-807.
11. von Scheidt W, Eng CM, Fitzmaurice TF, et al (1991) An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 324(6): 395-399.
12. Schiffmann R, Murray GJ, Treco D, et al (2000) Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci USA 97(1): 365-370.
13. Schiffmann R, Kopp JB, Austin HA 3rd, et al (2001) Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 285(21): 2743-2749.